SCHEMBL2493020

SCHEMBL2493020

COC(=O)C(NC(=O)c1ccccc1)C(C)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.55
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 5/20 0.46
LMNA P02545 4/20 0.46
GLA P06280 1/20 0.46
TSHR P16473 2/20 0.46
KDM4E B2RXH2 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
RAB9A P51151 2/20 0.44
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
SLC1A2 P43004 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP3A4 P08684 1/20 0.43
MAPT P10636 1/20 0.43
CTRB1 P17538 2/20 0.43
PRSS1 P07477 1/20 0.43
CTSG P08311 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9459921 0.91 GAA (0.59) GAAKMT2AALDH1A1LMNAGLA
SCHEMBL2486914 0.85 SMN1; SMN2 (0.51) GAAKMT2AALDH1A1RAB9AHPGD
SCHEMBL2486907 0.84 PRSS1 (0.49) GAAKMT2AALDH1A1LMNAKDM4E
SCHEMBL28458590 0.84 SLC1A2 (0.51) GAAKMT2AALDH1A1LMNAGLA
SCHEMBL10438915 0.82 GAA (0.51) GAAKMT2AALDH1A1LMNAGLA
SCHEMBL14714459 0.79 HPGDS (0.55) GAAALDH1A1LMNATDP1RAB9A
SCHEMBL1686722 0.79 GAA (0.58) GAAKMT2AALDH1A1KDM4ETDP1
SCHEMBL10502948 0.79 GAA (0.58) GAAKMT2AALDH1A1LMNAGLA
SCHEMBL9943346 0.79 GAA (0.58) GAAKMT2AALDH1A1KDM4ETDP1
SCHEMBL14786692 0.77 CYP26A1 (0.55) GAAALDH1A1RAB9ASMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966214-B9 TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2017-09-13 EP disclosed
EP-1966214-B1 TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2016-11-02 EP disclosed
EP-2227475-B1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN INC (US) 2014-02-19 EP disclosed
US-8269008-B2 Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions FIBROGEN, INC. (US) 2012-09-18 US disclosed
CN-101374843-B Triazolopyridazines as tyrosine kinase modulators JANSSEN PHARMACEUTICA NV 2012-09-05 CN disclosed
US-8173654-B2 Triazolopyridazine compounds JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-08 US disclosed
US-8030305-B2 Triazolopyridazines as kinase modulators JANSSEN PHARMACEUTICA N.V. (BE) 2011-10-04 US disclosed
US-7851493-B2 Phenyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-12-14 US disclosed
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2010-12-02 US disclosed
EP-2227475-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS Fibrogen, Inc. (US) 2010-09-15 EP disclosed
EP-0959884-A4 1999-12-15 EP disclosed
EP-0959884-A1 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF UNIVERSITY OF PITTSBURGH (US) 1999-12-01 EP disclosed
US-5925660-A ENZYME INHIBITORS FOR PHOSPHATASE UNIVERSITY OF PITTSBURGH (US) 1999-07-20 US disclosed
US-5856506-A (OXAZOLYLCARBONYLAMINO)ETHYLAMINO GLUTAMATE DERIVATIVES UNIVERSITY OF PITTSBURGH (US) 1999-01-05 US disclosed
WO-1998004257-A1 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF UNIVERSITY OF PITTSBURGH (US) 1998-02-05 WO disclosed
US-5700821-A INHIBIT CELL PROLIFERATION UNIVERSITY OF PITTSBURGH (US) 1997-12-23 US disclosed
US-5330998-A Anticholesterol agents PFIZER INC. (US) 1994-07-19 US disclosed
EP-0389699-B1 Thiazolidinedione derivatives as hypoglycemic agents PFIZER (US) 1994-05-11 EP disclosed
EP-0389699-A1 Thiazolidinedione derivatives as hypoglycemic agents PFIZER INC. (US) 1990-10-03 EP disclosed
WO-1989008652-A1 THIAZOLIDINEDIONE DERIVATIVES AS HYPOGLYCEMIC AGENTS PFIZER INC. (US) 1989-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS HIF1AN, HIF1A, EGLN2 GAA 565/4885KMT2A 697/4885ALDH1A1 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.